Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Biotech/Pharma Business
-
By Jason Derry —Merck to Buy Biologics Division from Insmed Insmed Inc. and Merck have announced a deal in which Merck will purchase Insmed's research and production division and facility for developing follow-on biologics for $130 million (see Insmed press release). Merck will receive Insmed's follow-on biologics platform, and its development and production facility…
-
By Jason Derry —ZymoGenetics Licenses Ex-North American Rights to IL-21 ZymoGenetics, Inc. has announced that it has licensed the rights to development and commercialization of interleukin 21 (IL-21) outside North America from Novo Nordisk A/S. The agreement means that the Seattle-based biotech company now has worldwide rights to IL-21. ZymoGenetics has indicated that it…
-
By Donald Zuhn — The New York Times reported this evening that Pfizer has agreed in principle to acquire Wyeth for $68 billion. The Times notes that barring an 11th-hour twist, the deal, which would be the largest in the U.S. since March 2006, will be announced tomorrow morning. According to the Times, five…
-
By Jason Derry — Peptimmune and Novartis Sign $500 Million Deal Peptimmune Inc. and Novartis AG recently announced a licensing deal for Peptimmune's multiple sclerosis drug candidate, PI-2301. The deal gives Novartis an exclusive license to the drug candidate. Novartis will assume all responsibilities relative to clinical development, manufacturing, and marketing of PI-2301. The…
-
By Jason Derry —Medicines Co. to Buy Targanta The Medicines Company and Targanta Therapeutics have announced that Medicines Co. will buy Targanta for $42 million. Medicines Co. has agreed to increase the purchase price by an additional $1.20 a share if Targanta's oritavancin, a product for treating skin infections, is approved by the FDA…
-
By Donald Zuhn — Last week, we received a press release from PatentBuddy.com regarding an analysis of employment statistics performed by the patent networking website. PatentBuddy.com is an online database of patent attorneys and agents registered to practice before the U.S. Patent and Trademark Office. The website allows registered practitioners to create personal profiles…
-
By Jason Derry — Endo to Acquire Indevus On January 5, 2009, Endo Pharmaceuticals Holdings Inc. announced that it will buy Indevus Pharmaceuticals Inc. for an initial payment of about $370 million and an additional $267 million, based on certain milestones. Currently, Indevus has marketed products for the treatment of overactive bladder, prostate cancer,…
-
By Donald Zuhn — Earlier this week, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its third annual survey on venture investment. Perhaps not surprisingly, the trade organization forecasts that most sectors will see a continued slowdown in venture investment in 2009. The…
-
By Jason Derry — King Pharmaceuticals, Inc. has announced that it will purchase Alpharma Inc. for about $1.6 billion in cash. King had been trying to convince Alpharma to accept an offer for the past couple of months (see "King Pharmaceuticals Extends Tender Offer to Acquire Alpharma"). Alpharma has two marketed pain killer products,…
-
By Jason Derry — Stem Cell Sciences plc has announced an agreement with Pfizer Ltd., under which Stem Cell Sciences (SCS) will provide services that will support Pfizer's new regenerative medicine unit. The partnership provides Pfizer with access to SCS's research services, cell lines, media, and reagents. SCS provides its stem cell technology to…
Patent Docs 